934266-82-7

Basic information

• Product Name: 2-AMINO-5-BROMOTHIAZOLO[5,4-B]PYRIDINE
• Synonyms: 2-AMINO-5-BROMOTHIAZOLO[5,4-B]PYRIDINE;5-broMo-[1,3]thiazolo[5,4-b]pyridin-2-aMine;5-BroMo-thiazolo[5,4-b]pyridin-2-ylaMine
• CAS NO: 934266-82-7
• Molecular Formula: C₆H₄BrN₃S
• Molecular Weight: 230.089
• Mol File: 934266-82-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 382.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.950±0.06 g/cm3(Predicted)
• Refractive Index: 1.803
• PKA: 0.74±0.40(Predicted)
• CAS DataBase Reference: 2-AMINO-5-BROMOTHIAZOLO[5,4-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-BROMOTHIAZOLO[5,4-B]PYRIDINE(934266-82-7)
• EPA Substance Registry System: 2-AMINO-5-BROMOTHIAZOLO[5,4-B]PYRIDINE(934266-82-7)

Safety Data

• Hazardous Substances Data: 934266-82-7(Hazardous Substances Data)

Usage

General Description

2-Amino-5-bromothiazolo[5,4-b]pyridine is a chemical compound with the molecular formula C7H5BrN4S. It is a heterocyclic compound containing a thiazole ring fused to a pyridine ring, with a bromine and an amino group attached to the thiazole ring. 2-AMINO-5-BROMOTHIAZOLO[5,4-B]PYRIDINE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It exhibits potential biological activities such as antiparasitic and antitumor properties. 2-Amino-5-bromothiazolo[5,4-b]pyridine is also utilized in the research and development of novel drugs and chemical compounds.

InChI:InChI=1/C6H4BrN3S/c7-4-2-1-3-5(10-4)11-6(8)9-3/h1-2H,(H2,8,9)

Upstream product

• 169833-70-9 6-bromo-2-chloropyridine-3-ylamine 
• 13534-97-9 6-bromopyridine-3-amine 
• 1112982-76-9 N-(5-bromothiazolo[5,4-b]pyridin-2-yl)acetamide 
• 4487-59-6 2-bromo-5-nitropyridine 
• 5418-51-9 5-nitro-2-hydroxypyridine 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 934266-81-6 4-{4-[1-(5-bromo-thiazolo[5,4-b]pyridin-2-ylcarbamoyl)2-cyclopentyl-ethyl]benzenesulfonyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1202053-83-5 4-acetyl-N-(5-bromothiazolo[5,4-b]pyridin-2-yl)benzamide 
• 1202053-85-7 N-(5-bromothiazolo[5,4-b]pyridin-2-yl)-4-tert-butylbenzamide 
• 1202053-80-2 Methyl 4-(5-bromothiazolo[5,4-b]pyridin-2-ylcarbamoyl)benzoate 
• 1202053-82-4 N-(5-bromothiazolo[5,4-b]pyridin-2-yl)-4-(1-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yl)benzamide 
• 1112982-76-9 N-(5-bromothiazolo[5,4-b]pyridin-2-yl)acetamide 
• 1253411-08-3 C₂₆H₂₆N₄O₃S 
• 1253415-51-8 C₁₉H₁₉N₃O₃S 
• 1253415-52-9 C₁₄H₁₁N₃OS 
• 1446854-44-9 5-(2-methoxyphenyl)thiazolo[5,4-b]pyridin-2-amine 
• 1440428-02-3 C₆H₂Br₂N₂S 
• 1616589-57-1 5-(2-acetamidothiazolo[5,4-b]pyridin-5-yl)-3-(4-fluorophenylsulfonylamino)-2-methoxybenzamide 
• 1616589-58-2 5-(2-(cyclopropanecarboxamido)thiazolo[5,4-b]pyridin-5-yl)-3-(4-fluorophenylsulfonylamino)-2-methoxybenzamide 
• 1616589-59-3 5-(2-(cyclopropylamino)thiazolo[5,4-b]pyridin-5-yl)-3-(4-fluorophenylsulfonylamino)-2-methoxybenzamide 

Relevant articles and documents

FUSED AZOLE HETEROCYCLES AS AHR ANTAGONISTS

The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.